The trial attained the two its Major endpoints, with semaglutide 2.4 mg demonstrating statistically sizeable and exceptional advancements in liver fibrosis without worsening of steatohepatitis, and also resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH in comparis